Relationships are important -- especially when there's a massive effort to distribute COVID-19 vaccines under way. There have been reports recently, though, hinting that Pfizer's (PFE 2.40%) relationship with the U.S. government could be strained. In this Motley Fool Live video recorded on Dec. 18, 2020, healthcare and cannabis editor/analyst Olivia Zitkus and writer Keith Speights discuss what's behind the feud between Pfizer and the feds.

10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of November 20, 2020


Olivia Zitkus: There seems to be some confusion between the federal government and Pfizer about whether the number of doses that are set to be delivered are on schedule or whether they are enough. Pfizer published a message just yesterday, I believe, rebutting that they don't have enough doses and putting the logistics failure on the government, saying, "We do have enough, it's here. Something else is going wrong."

What do investors need to know about the situation?

Keith Speights: [Laughing] I think investors shouldn't be too concerned about any of this. Maybe there's a little bad blood between Pfizer and the government here.

If you recall, when Pfizer came out with those great efficacy results last month, there were some in the government who tried to take credit for Pfizer's success, and Pfizer quickly came back and said, "Hey, we funded this ourselves, [laughs] and we took all the risk." Some in the government said, "Oh, no. You were part of Operation Warp Speed," and Pfizer said, "No, we really weren't. We just received a purchase order, but all the risk was on our part."

So I think there's maybe a little bit of a riff here, and I think it probably manifested itself a little bit this week with HHS Secretary Azar saying that there were some distribution challenges Pfizer was experiencing. Pfizer came back and said, "No, we've got doses that the government hasn't even told us where to ship." So a little bit of contention there, but I don't think it's anything for investors to be concerned about at all.

Olivia Zitkus: That's great. Pfizer maintains that they will be ready to deliver their 500 million doses globally next year and did say that they are waiting on further instructions. [laughing]

Keith Speights: Yeah. My personal opinion is I tend to believe what Pfizer is saying. [laughs] They have the vaccines after all, right? 

Olivia Zitkus: That's true, they hold the vaccine.

Keith Speights: They have more information. [laughs]